Objectives: This study examined Klebsiella pneumoniae clinical isolates and their bla KPC plasmids to determine potential relatedness of the isolates and their plasmids harbouring carbapenem resistance mechanisms.
Introduction
The first Klebsiella pneumoniae carbapenemase (KPC) (KPC-1/2) was discovered in North Carolina during the Intensive Care Antimicrobial Resistance Epidemiology (ICARE) surveillance project in 1996. 1 Since then, KPCs have been reported from China, Israel, Europe, South America and Canada, 2 with 10 current variant sequence types (STs; KPC-1/2 to -11) identified. KPCs are predominantly found in Enterobacteriaceae, although recently they have been described in Pseudomonas aeruginosa and Acinetobacter spp. 2 The KPC enzyme has the ability to hydrolyse all b-lactams (except cephamycins). 3 The bla KPC gene is harboured on plasmids and carried within the transposon Tn4401, 4 suggesting the potential mobility of this gene both within and between bacterial species. To further investigate the potential for transmission of bla KPC we characterized K. pneumoniae isolates harbouring bla KPC from New York City (NYC) and Toronto.
Materials and methods

Bacterial isolates
Twenty-one KPC K. pneumoniae, consisting of 19 isolates from New York Presbyterian Hospital, New York, NY, USA, collected in 2007 and 2 isolates from Toronto, Canada, collected in 2008 and 2009, were sent to the National Microbiology Laboratory, Winnipeg, Canada. All isolates were tested for carbapenemase production using the modified Hodge test (MHT) with 10 mg of ertapenem following the 2009 CLSI guidelines.
Molecular typing
Isolates were typed by PFGE using XbaI-digested genomic DNA on a Chef-DRIII System (Bio-Rad, Mississauga, ON, Canada) and analysed with BioNumerics software (version 3.0; Applied Maths, Saint Martens-Latem, Belgium). All PCR products were sequenced using primers found in Table S1 (available as Supplementary Online). Multilocus sequence typing (MLST) was performed according to the K. pneumoniae protocol described on the MLST web site (http:// www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html).
Antimicrobial susceptibility testing
Antimicrobial susceptibilities were determined by automated broth microdilution using CMVIAGNF and ESB1F panels (Sensititre TM , Trek Diagnostics, Ohio, USA) with 2009 CLSI breakpoints. Ertapenem, tigecycline and colistin MICs were determined by Etest (AB Biodisk, Solna, Sweden). MICs of colistin followed CLSI breakpoint criteria for Acinetobacter spp. (susceptible, MIC≤2 mg/L; resistant, MIC≥4 mg/L). MICs of tigecycline were defined based on the FDA breakpoint criteria for Enterobacteriaceae (susceptible, ≤2 mg/L; intermediate, 4 mg/L; resistant, ≥8 mg/L).
Plasmid characterization
Plasmid DNA was isolated using Qiagen plasmid kits (Qiagen Inc., Mississauga, ON, Canada). Plasmids harbouring bla KPC were transformed into E. coli ElectroMax TM DH10B cells (Invitrogen, Carlsbad, CA, USA) and selected on Luria-Bertani (LB) plates containing 50 mg/L ampicillin. bla KPC plasmids were digested with EcoRI (Roche Diagnostics, Laval, QC, Canada) and analysed by electrophoresis on a 0.7% gel at 80 V for 5 h.
Plasmid incompatibility grouping was determined by PCR. 5 PCR mapping of the Tn4401 element was conducted using previously described primers. 4 
Outer membrane analysis
Outer membrane protein (OMP) gene amplification was conducted using Ompk35-F and -R and Ompk36/omp36-F and -R 6 and sequenced using OMP primers (Table S1 ).
Nucleotide accession numbers
The ompK36 sequences for K. pneumoniae isolates N09-00043, N09-00057 and N09-00083 were assigned accession numbers HM769259, HM769260 and HM769261, respectively, in the GenBank database. The bla KPC gene and flanking region harboured by K. pneumoniae N09-00048 was assigned accession number HM769262.
Results and discussion
Clinical features and patient demographics of the case
The first KPCs in Canada were reported recently from Ottawa, ON, 7 with evidence suggesting intra-hospital transmission from Indeed, all isolates in this study, with the exception of one, were MDR, which we defined as resistance to at least three different antimicrobial classes, including resistance to tigecycline (n¼ 2) and colistin (n¼ 4) ( Table 1 ).
Molecular typing of the isolates
DNA fingerprinting revealed a large cluster containing 17 (15 NYC and 2 Toronto) K. pneumoniae that shared ≥80% similarity (Figure 1) , with the remaining 4 isolates having unique PFGE pattern types. The cluster contained isolates harbouring both KPC-2 (n¼ 12) and KPC-3 (n¼ 5). MLST was conducted on 12 isolates inside and 4 outside of this cluster. Five STs were observed ( Figure 1 ). The PFGE cluster contained isolates that belonged to ST258, with the exception of N09-00049 (ST418), which contained a single locus variant (allele rpoB) to ST258. Outside the PFGE cluster, ST414, ST111 and a novel ST417 were observed. ST258 has been reported internationally and may represent a clonal group contributing to KPC dissemination. 8, 9 It is therefore not surprising that this was the dominant clonal type in our collection, which included both Canadian isolates. This is the first report of ST258 in Canada.
KPC plasmid analysis
Plasmids ranged from 38 to 135 kb in size. The bla TEM-1 gene was associated with 90.5% (n¼ 19) of KPC plasmids. Replicon typing revealed 47.6% (n¼ 10) repFllA, 14.3% (n¼ 3) repR, 4.8% (n¼ 1) repColE and 33.3% (n¼ 7) unidentified replicon types. pRFLP analysis revealed three clusters with ≥80% similarity: pKPCA, -B and -C (Figure 1 ). Cluster 1 (pKPCA1-A3, n¼ 9, KPC-2, repFllA) contained KPC plasmids from both Toronto and NYC. Similarly, repFIIA has been observed both in North America and Europe, 10 revealing a common KPC plasmid backbone. Isolates that belonged to K. pneumoniae ST258 (n ¼12) contained diverse KPC plasmids and were identified in all three pRFLP clusters, indicating no relationship between ST type and plasmid type. Interestingly, the two Toronto isolates were in the same PFGE cluster, but pRFLP patterns differed dramatically (Figure 1 ), suggesting the movement of the bla KPC gene between plasmids within similar isolates.
PFGE-Xbal
Plasmid-EcoR1 Strain Tables 1 and 2 . Contrary to the clinical isolates, transformants were not resistant to imipenem or meropenem. Reduced susceptibility to ertapenem was observed in seven transformants. Lower MICs to carbapenems in KPC transformants as compared with clinical isolates have been previously reported by investigators 4 and suggest the presence of additional mechanisms of resistance, such as OMP alterations 6, 11 and the presence of additional b-lactamases not located on the KPC-containing plasmid. MDR was detected in 23.8% (n¼ 5) of KPC plasmids where resistance to cephalosporins, aminoglycosides, chloramphenicol and folate pathway inhibitors has been commonly observed.
Both the clonal spread of K. pneumoniae with unrelated KPC plasmids as well as genetically similar KPC plasmids within genetically distant K. pneumoniae were observed (Figure 1) , suggesting horizontal transfer and clonal expansion as mechanisms of bla KPC dissemination.
Region surrounding bla KPC
The identification of bla KPC on the transposon Tn3-like Tn4401 has been suggested as an important factor in its worldwide dissemination. 4 This conserved element contains a polymorphic region between the istB of the ISKpn7 and bla KPC gene where 100, 200 and 255 bp deletions have been observed. 4, 9 Sequencing of the regions surrounding the bla KPC gene was conducted on all isolates, including the intergenic region between istB and bla KPC , revealing the presence of Tn4401. 4 We found 71.5% (n¼ 15) of isolates contained the 100 bp deletion (Tn4401a), 9.5% (n ¼2) contained no deletion (Tn4401b) and 19% (n¼ 4) contained a novel 68 bp deletion (GenBank accession no. HM769262). KPC-2 was found exclusively in Tn4401a and KPC-3 was associated with Tn4401a, Tn4401b and the isoform that contained the 68 bp deletion. It is unknown if differing isoforms have any effect on the MIC.
OMP gene analysis
Recent studies have shown that alterations in the OMP of OmpK35 and OmpK36 have contributed to CARB-R. 6, 11 Low-level MICs of carbapenems in transformants compared with clinical isolates led to the investigation of OMPs. ompk35 (n¼ 14) and ompk36 (n¼ 12) were sequenced, which represented the main PFGE cluster and the four unique fingerprint types (Figure 1 ). Eleven (78.6%) clinical strains contained a frameshift mutation in ompk35 due to the insertion of a G (nucleotide position 122) that resulted in a premature stop codon at amino acid position 89, which may lead to the early termination of the peptide. Eight Table 2 . MICs (mg/L) of b-lactams for clinical (C) isolates and transformants a (T) Mataseje et al.
strains had an OmpK36 identical to that from K. pneumoniae VM522, an isolate belonging to a clonal group endemic to the NYC region previously shown to harbour KPC, where the reduced expression of ompk36 was observed. 11 Three strains had unique OmpK36 proteins. Although we did not look at expression levels of the ompK35 and ompK36 genes, it has been shown that differing levels can affect MICs to carbapenems.
11
Concluding remarks
This report is the largest study of its kind to date to examine plasmids harbouring the KPC genes and the first to characterize Canadian KPC-producing K. pneumoniae at the molecular level. We identified novel K. pneumoniae genetic backgrounds containing KPC genes, further supporting the mobility of KPC plasmids. We described three distinct KPC plasmid clusters, including the first observations of KPC plasmids with repR types, further demonstrating the mobility of the KPC gene. We have provided further evidence to support the theory that carbapenem resistance is multifactorial and involves the contribution of carbapenemases, additional b-lactamases, as well as mutations in porins observed in clinical isolates.
Funding
This work was supported by the Public Health Agency of Canada.
Transparency declarations
None to declare. Table S1 is available as Supplementary data at JAC Online (http://jac. oxfordjournals.org/).
Supplementary data
